Jasmine Gill
Psychiatry · Newtown, PANPI 1164747697
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 25.8% of the total. 2025 is the largest year on record at $880, more than ten times the $76 reported in 2019.
Across 151 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$788
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$484
- Ironshore Pharmaceuticals Inc.$325
- Tris Pharma Inc$193
- Otsuka America Pharmaceutical, Inc.$167
- Axsome Therapeutics, Inc.$151
- plus $945 from 15 others
What the payments were for
- Food & beverage$3,055100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $788 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $484 |
| Ironshore Pharmaceuticals Inc. | 14 | $325 |
| Tris Pharma Inc | 11 | $193 |
| Otsuka America Pharmaceutical, Inc. | 10 | $167 |
| Axsome Therapeutics, Inc. | 7 | $151 |
| Supernus Pharmaceuticals, Inc. | 6 | $115 |
| E.r. Squibb & Sons, L.L.C. | 4 | $107 |
| Corium, LLC | 5 | $102 |
| Alkermes, Inc. | 4 | $100 |
| Collegium Pharmaceutical, Inc. | 5 | $95 |
| Lundbeck LLC | 4 | $93 |
| Neurocrine Biosciences, Inc. | 3 | $80 |
| Bausch Health US, LLC | 2 | $47 |
| Johnson & Johnson | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Indivior Inc. | 2 | $30 |
| Braeburn Inc. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| OWP Pharmaceuticals, Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$125
How this compares
$3,055 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $352 |
| Hydroxyzine Pamoate | 14 | $144 |
| Diazepam | 13 | $115 |
| Escitalopram Oxalate | 11 | $40 |
| Lamotrigine | 18 | $33 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Newtown
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.